Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
BC 11-38Cat. No. 4496 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 6,7-Dihydro-3-phenyl-2-(propylthio)thieno[3,2-d]pyrimidin-4(3H)one |
Biological Activity
Selective phosphodiesterase (PDE) 11 inhibitor (IC50 = 0.28 μM for PDE11; IC50 values are >100 μM for PDE1 - PDE10). Significantly elevates cAMP levels and cortisol production in H295R human adenocarcinoma cells.Certificate of Analysis / Safety Data Sheet
Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet
References
Ceyhan et al (2012) Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chem.Biol. 19 155. PMID: 22284362.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: BC 11-38, supplier, BC11-38, phosphodiesterase, pde, 11, inhibitors, selective
Quick Order
Find multiple products by catalog number
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
New Products in this Area
3-Cyano-7-ethoxycoumarin
Fluorescent cytochrome P450 substrate
Sign-up for new product e-alerts
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK